Maruho Entered into an Exclusive License Agreement with Alchemedicine to Develop and Commercialize Aldehyde Dehydrogenase 2 Activator
Shots:
- Alchemedicine will receive an up front, development & commercial milestones along with royalties based on sales. The companies collaborated to develop & commercialize Alchemedicine's aldehyde dehydrogenase 2 (ALDH2) activators after Maruho exercised the option right included in the exclusive negotiation & evaluation agreement
- Maruho to get an exclusive right globally to develop, manufacture & commercialize the compound in designated disease areas & lead the development of drugs using the compound as an active ingredient
- Alchemedicine’s focus is to develop compounds for drug candidates using the medicinal chemistry platform HiSAP. Both companies are dedicated to continuing to improve QoL for patients by providing new therapeutic agents
Ref: Maruho | Image: Maruho
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
